Eli Lilly’s Mirikizumab Shows Promise in Treating Crohn’s Disease, Faces Competition from AbbVie’s Skyrizi
The phase III VIVID-1 study demonstrated exceptional potential, meeting all primary and secondary benchmarks over a 52-week treatment span. Eli Lilly has unveiled promising results for its experimental drug, mirikizumab (Omvoh), in the treatment of moderate-to-severe Crohn’s disease (CD) Impressively, 51.4% of CD patients achieved clinical remission on the drug, a substantial surge compared to…